Targovax ASA has reconfigured its portfolio to put priority on the development of a candidate oncolytic virus for cancer which has shown promising early clinical results in mesothelioma and checkpoint inhibitor refractory melanoma.
The trial results for ONCOS-102, the oncolytic virus, were highlighted in the Norwegian company’s financial report for the third quarter, which showed a cash balance of NOK 173 million (€18.2 million) on 30 September, down from NOK 261.6 million on 31 December 2017.